Aoife Brennan/LinkedIn
Jun 12, 2026, 14:27
Aoife Brennan: Ongoing Budo Study Demonstrates Potential in Challenging ITP Population
Aoife Brennan, Board Member at Critical Path Institute (C-Path), President and CEO of Climb Bio, shared a post on LinkedIn:
“Delighted to share data from our ongoing study of budo in ITP today at EHA.
Many of the patients enrolled had a higher number of prior lines of therapy than baseline platelet count which illustrates the need for new treatments that provide durable treatment response.
Immense gratitude to the patients and investigators who are participating and congratulations to the team Climb Bio.”
Stay updated with Hemostasis Today.
-
Jun 12, 2026, 14:15Shahram Kordasti: A Well-Deserved Honor at EHA 2026
-
Jun 12, 2026, 14:12Ahvie Herskowitz: Beyond Weight Loss – Lessons From the GLP-1 Era
-
Jun 12, 2026, 14:06Elizabeth Clift: Pride Month Through the Lens of Haemophilia
-
Jun 12, 2026, 13:46Katherine Simbaña Rivera: Understanding Thromboembolic Risk After COVID-19
-
Jun 12, 2026, 13:38Bruna Velosa Ferreira: Lessons in Leadership, Mentorship, and Humanity from EHA 2026
-
Jun 12, 2026, 13:33Astha Thakkar: Understanding Anti-Platelets vs. Anti-Coagulants – When to Use Which?
-
Jun 12, 2026, 13:21Walaa Abuelmagd: Honoring Excellence and Inclusion at the EHA 2026 Congress
-
Jun 12, 2026, 13:16Leonardo Roever: What 73,000 Patients Teach Us About Blood Pressure and Stroke Risk in Dementia
-
Jun 12, 2026, 13:09Pramit Mukherjee: A Milestone in Understanding Mechanical Thrombectomy for In-Hospital Stroke